Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
Chemistry & Biochemistry
US 20170204390 A1
Board of Trustees of the University of Arkansas (Little Rock, AR); Montefiore Medical Center (New York, NY); Kitasato Institute (Tokyo, JP); National University Corporation Kagawa University (Kagawa, JP)
Ponnapakkam, T., Philominathan, S. T., Sakon, J., Katikaneni, R., Koide, T., Matsushita, O., Gensure, R. C., & Nishi, N. (2021). Delivery of therapeutic agents by a collagen binding protein. Patents Granted. Retrieved from https://scholarworks.uark.edu/pat/415